UK today, the underlying problem has to be dealt with.
The industry has a long history of service to the professions and by its very nature is required to study and meet their changing needs. It recognizes the fact that today its chief customers, or more accurately its paymasters in this country, are the Department of Health and Social Security and the equivalent Departments in Scotland, Wales, and Northern Ireland, and it is as willing to consider and meet their requirements as it is to serve the medical and pharmaceutical professions. The Health Departments have also clearly demonstrated their concern for the national interest, not only in the field of public health, but also in the promotion of an inventive, productive and efficient industry in the UK.
Against this background there can be one significant gain from the public discussion that has followed the publication of the Sainsbury Reporta recognition that more information available to both the Health Department and to the industry can lead to a continuing and fruitful dialogue between the parties, that must result in better understanding and a resolution of such problems as arise, based on mutual respect and a full appreciation of each other's views and needs. Dr The theme of this meeting lends itself to division into two parts -the medicines and the community. In both parts government has a role to playin the former in connexion with the safety, quality, and efficacy of manufactured preparations, and in the latter with the use of these preparations by the medical profession and the public. These two areas of concern involve regulation on the one hand and education on the other. In addition, when a nation has a comprehensive National Health Service the state becomes automatically the largest single purchaser of medicines and this leads to further special responsibilities. All these considerations will be dealt with briefly, beginning with safety, quality and efficacy.
Safety, Quality and Efficacy of Medicines
Until the Medicines Act 1968 is brought into effect the control of safety, quality and efficacy remains covered by a patchwork of statutory, quasi-statutory, and non-statutory mechanisms.
The oldest was the quality control exerted by the publication in works such as The British Pharmacopceia, The British Pharmaceutical Codex, and The British Veterinary Codex of monographs describing substances and laying down certain standards for them. Although The British Pharmacopaia has statutory authority in parts of the Commonwealth it has not had such standing in its country of origin, being used as presumptive evidence under the British system of case law. The British Pharmacopwia has been a responsibility of the General Medical Council ever since the Council was brought into being by the Medical Act of 1858, but the Medicines Act of 1968 calls for the ending of this at a date not yet specified, when this text will come under a special committee under the aegis of the Medicines Commission. It will then be an official compilation of standards.
The first world war delayed development of hormones, enzymes, and blood products up to the present time. The Penicillin Act of 1947, among other functions, exerted similar controls over the quality of injectable forms of this antibiotic but has since been incorporated in the Therapeutic Substances Act of 1956 and expanded so that the quality of a number of injectable antibiotics is now controlled. The Food and Drugs Acts and the Pharmacy and Medicines Acts have also played a small part in this patchwork control by restricting adulteration and calling for declaration of composition.
However, all these measures were concerned mainly with the quality of medicines and only indirectly with safety. While safety and quality are intimately associated in the case of biological substances the linkage is not quite so direct for chemical preparations. Very broadly speaking, however, chemical medicines of great potency were not abundant before the second world war and were used only for the treatment of serious disease; the only statutory control, in the form of the Therapeutic Substances Act, seemed then to serve as a sufficient safeguard.
The tragedy associated with thalidomide upset this balance of control, making it apparent that something more was needed over and above simple descriptive standards. A committee was set up to advise on safety and in 1963 reported, recommending, essentially, the system represented by the present Committee on Safety of Drugs under Sir Derrick Dunlop. This voluntary system has been in operation now for five years with great success and has revealed and solved many problems which should enable the Medicines Act to get under way from a good start.
The Committee has functioned essentially as an external auditor and counsellor, in its Medical Assessor's phrase, providing an independent professional judgment rather than a set of rules and regulations. It has been concerned, as a fundamental principle, in no way to diminish the responsibility of the manufacturer for the safety of his product or the responsibility of the clinician for the safety in use of the drugs he prescribes.
The Committee has taken the form of a main or policy-making Committee served by three Subcommittees. Two of these have recently always sat jointly and consider the evidence on new drugs or new drug formulations before they are either submitted to clinical trial or put on the market. Before a drug is submitted to clinical trial, the evidence of pharmacological effects and of toxicity in animals is considered. However, it is not always possible to predict, by animal experimentation, what side-effects will be produced by a drug in man; and the stage of clinical trials, if the Committee raises no objection to these being undertaken, must normally start in not more than three approved centres. Even very extensive clinical trials, however, may fail to detect some serious reactions, such as jaundice or blood dyscrasias, occurring perhaps in only one in 10,000 patients treated. A monitoring system is therefore required to detect adverse reactions after drugs have been introduced into general use and to enable early warning to be given of any dangers. The Committee has set up a third Subcommittee for this purpose.
At this point a warning must be issued. Almost any drug which is effective is likely to have its own dangers; toxicity is the price to be paid for the potency of the remedies which have transformed the practice of medicine in little more than thirty years. However careful industry and regulatory agencies are in testing, or the doctor in prescribing, the possibilities of risk from a new drug can only be minimized, never entirely eliminated.
One essential way in which doctors can help to contain these risks is to report suspected reactions to the Subcommittee on Adverse Reactions and some 15,000 reports have been registered in this way during the past five years. Nevertheless, the quantity remains disappointing and there is good reason to believe that when genuine adverse reactions occur they tend to be under-reported. However, a number of drugsafety problems have been identified and assessed. In some cases it may be necessary to go further and mount a special epidemiological investigation for this purpose. One such study was the collaborative inquiry by the Committee on Safety of Drugs, the Medical Research Council and the Royal College of General Practitioners which established for the first time that the use of oral contraceptives produces a significant increase in the incidence of thromboembolic disease.
Even before the setting up of the Committee on Safety of Drugs there had been general moves towards tidying up and extending the miscellaneous legislation on medicines. These moves have culminated in the passing of the Medicines Act of 1968. This Act calls for the setting up of a Medicines Commission to be appointed by the relevant Ministers to advise them on all matters relating to human and veterinary medicines. At long last the attributes of quality and safety and efficacy of medicines are brought together under a common head.
The Medicines Commission will be a body of independent experts in no way confined in the professional advice they give. Until they are appointed one can only speculate about their method of working but historical experience suggests that the emphasis will remain, as it has always been, on the responsibility of the manufacturers and/or the marketers for their own preparations. This is a rather different attitude from that of the Food and Drugs Authority of the United States of America which has assumed much more of the manufacturers' responsibility, laying down detailed requirements for testing and carrying out in its own laboratories a parallel batch control. In this country parallel batch control has been reserved for 'biological' substances under two main headings: substances being made for the first time by a manufacturer or substances containing a living virus. A recent report of the Pan-American Health Organization would also indicate that drug control at present exerted or proposed by the Latin American countries emphasizes far more the laboratory analysis of samples than the use of expert assessment and advice. A similar state of affairs exists in Japan where control is based largely upon parallel batch testing in a central laboratory. Our attitude is more akin to that operated in America by the National Institutes of Health upon biological preparations. This is not surprising in view of the historical development of the Medicines Act as arising from an amalgam of the Committee on Safety of Drugs and the Therapeutic Substances Act, the latter being drawn up after study of the then existing American system now operated by NIH. A similar system is operated at present in Denmark and Sweden extending to the other Scandinavian countries in partnership. A study of systems overseas is of importance because of the international character of the pharmaceutical industry and the increasing importance of free trade.
Comparative Efficacy
The notion of 'efficacy' as it applies to medicines will now be examined a little more closely. The Committee on Safety of Drugs has always been quite clear about the meaning to be attached to this in the context of its own deliberations. Efficacy is considered in relation to safety and only in this relationship. Thus a medicine used for the treatment of an otherwise fatal condition, if it has some efficacy, can have a lower margin of safety than a trivial remedy. If a medicine has no proven efficacy for the treatment of a particular condition and has evident toxicity then it cannot be accepted treatment for that condition. The aim is always to strike a balance between clinical benefit and probable risk. However, there are also circumstances in which government is bound to be concerned about the comparative efficacy of drugs over and above considerations of safety. When a comprehensive National Health Service exists central government must try to ensure that finance is not wasted. Medicines cost money! Hence government is required to attempt to reduce any possible waste of money from this source. Fundamentally, this can only be done by educational methods: education of both the prescriber and the consumer of the medicine. In a country such as Britain where individual freedom is jealously guarded the method must be that of education and not control; the doctor must retain his full responsibility for what he prescribes. The report of the Committee of Inquiry into the Relationship of the Pharmaceutical Industry with the National Health Service laid great stress on the need for education and recommended that the Medicines Commission should play an active role in this. Account had already been taken of the principles underlying some of its recommendations in the preliminary work on the Medicines Actincluding that of exercising some degree of supervision and control over the educational efforts of the pharmaceutical industry. Such influence is not new. The industry itself has made valiant efforts to keep its own house in order, and misleading advertising of an obvious character has been legislatively controlled in the past.
In 1948 it was clear that there was need of some further means of providing the profession with authoritative and up-to-date guidance on the many drugs at its disposal and the Minister accordingly, on the advice of his Standing Medical Advisory Committee, set up a Joint Committee of the Central and Scottish Health Services Councils; this committee and a succeeding committee advised the Minister until 1963 on the classification of proprietary preparations with regard to the justification for their use.
With the establishment of the Committee on Safety of Drugs in June 1963, the Central and Scottish Health Services Councils reviewed the composition and terms of reference of the Joint Committee on the Classification of Proprietary Preparations. As a result a new and smaller committee was set up under the chairmanship of Professor Alastair Macgregor of Aberdeen University whose terms of reference were, broadly speaking, to classify drugs and thus help doctors choose which drugs should be used in the treatment of their patients, to identify preparations the prescribing of which would appear to call for special justification and to distinguish drugs from foods, toilet preparations, and disinfectants.
The Macgregor Committee has interpreted its terms of reference as implying an educative responsibility. In classifying certain mixtures as undesirable, for example, the Committee has published the grounds on which its opinion is based. The work of the Committee should be seen in context as simply a part of an educational effort, other elements of which are exemplified by the Prescribers Journal, and the Drugs and Therapeutics Bulletin. These are activities for which it is right that independent bodies should be responsible. Cost, however, is a matter for the Department of Health and Social Security in view of its National Health Service responsibilities, and hence the Department issues the costhistograms and similar material. All these, however, should be secondary to the primary method of pre-and post-graduate education of the prescriber in the sensible use of medicines and the broader effort of creating a restrained and knowledgeable public demand. The doctor today is faced with several thousand prescribable remedies. About 50 new substances come before the Committee on Safety of Drugs each year and at least ten times as many new formulations; few of these can have more than a five-year life in general use. Such a situation creates formidable problems of communication even in the favourable circumstances of hospital and much more so in general practice. A doctor cannot hope to become familiar with the properties of all the drugs at his disposal. He therefore needs to limit his personal pharmacopeeia to those about which he has knowledge or reliable authority. To do even this properly will require a more thorough grounding in the principles of therapeutics than is as yet common in medical schools. Furthermore, he will need to refresh his knowledge throughout his professional career. This seems one of the most important contributions that postgraduate medical education can make in the future and in order to do that the specialty of clinical pharmacology must grow. Without it there is not only a great deal of wasteful and unscientific prescribing; it is still possible for a drug like chloramphenicol, with well-known and serious hazards, to be quite widely used in conditions, some of them trivial, for which it is in no way indicated.
Misuse
Finally, a problem should be mentioned for which doctor and patient must each bear a share of responsibility. Over-supply of medicines is all too common. This leads to drugs being dispersed throughout our homes, to a temptation to misuse and abuse and to a risk of poisoning, the effects of which are revealed in our morbidity and mortality statistics. It is clear that a great deal of education of doctors is required and a great deal of education of patients by doctors. In this process, government should doubtless play a part by ensuring the provision of balanced and reliable information from experts. Industry, too, could help, not only educationally, but also possibly by some modifications of its present system of marketing, such as the introduction of a form of container and labellingfor example, strippackingwhich would make it easier to prevent errors of identification, simplify dosage for the patient, limit individual supplies more to needs and provide against surpluses likely to be misused.
To sum up, the safety of medicines is a shared responsibility between government, industry, prescribing doctor and public; and each of these in their own field of responsibility must play their part.
